CDK2AP1 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R547 is a small molecule inhibitor of CDK2AP1 that has shown potential in research studies as an anti-cancer agent. It was developed by Rigel Pharmaceuticals and was being investigated for its ability to disrupt cell cycle progression. | ||||||
UCN-01 | 112953-11-4 | sc-202376 | 500 µg | $251.00 | 10 | |
UCN-01 is a natural product-derived compound that inhibits multiple CDKs, including CDK2APWhile its primary mechanism of action is the inhibition of protein kinases, it also affects CDK2AP1-mediated functions. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a CDK inhibitor that targets various CDKs, including CDK2APIt has been studied for its potential anti-cancer effects by inducing cell cycle arrest and apoptosis. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone is a small molecule inhibitor that targets several kinases, including CDK2APIt has been explored in research as a potential anti-cancer agent due to its impact on cell cycle regulation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a synthetic flavonoid compound that inhibits multiple CDKs, including CDK2APIt has been investigated for its potential to block cell cycle progression and induce apoptosis in cancer cells. | ||||||
PHA 767491 hydrochloride | 942425-68-5 | sc-204187 sc-204187A | 10 mg 50 mg | $198.00 $802.00 | 3 | |
PHA-767491 is a selective CDK inhibitor that affects CDK2AP1 as well as other CDKs. It has been studied for its potential to inhibit tumor growth by disrupting cell cycle control. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 is a multi-CDK inhibitor that includes CDK2AP1 among its targets. It has been evaluated in research and early clinical studies for its anti-cancer properties. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor that affects CDK2AP1 and other CDKs. It has been investigated for its potential to suppress cancer cell growth and enhance apoptosis. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
While primarily known for its inhibition of CDK4/6, PD-0332991 also affects CDK2AP1 to some extent. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Similar to PD-0332991, LY2835219 is a CDK4/6 inhibitor with some activity against CDK2AP | ||||||